1. Design
Protocol review, endpoint and estimand definition, sample size, CRF and edit check specification, and a documented data flow mapped against country requirements.
Solutions · Clinical Data Management and Biostatistics | Guosa Life Sciences
Data Integrity. Statistical Confidence. Better Decisions.
Clinical data are among the most valuable assets generated during development. Their integrity directly influences scientific conclusions, regulatory decisions and patient outcomes.
Overview
As study designs grow more complex and data sources expand, organizations require integrated data management and statistical expertise that ensures reliable, high-quality evidence.
Guosa Life Sciences integrates robust data governance, advanced analytics, statistical expertise and compliant systems to transform clinical information into meaningful scientific insight.

Capabilities
The GLS Advantage
Every solution delivered by Guosa Life Sciences is strengthened by the broader enterprise. Our operational teams are supported by evidence-based Insights, professional development through GLS Academy, collaborative partnerships within the Clinical Development Network and a quality-driven delivery model, enabling scientifically sound, operationally efficient and scalable solutions.
The capability
We build and run the data layer: EDC design and build, edit check specification, data validation and cleaning, medical coding, external data reconciliation, database lock, statistical analysis plan development, analysis and reporting, and the datasets and define documentation a submission requires.
Biostatistics is involved from protocol stage rather than at analysis. Endpoint definition, sample size assumptions and the handling of intercurrent events are decisions that determine whether a study can answer its question, and they are far cheaper to get right before enrollment than to defend afterward.
Regulatory considerations
Clinical data crossing borders now engages national data protection law in most of the markets a multi-country study touches. Requirements differ materially: some jurisdictions require local storage of personal data, others permit transfer subject to adequacy or contractual safeguards, and several require registration or notification before processing begins. Consent language must reflect the actual data flow, including onward transfer to a sponsor or vendor in a third country.
The practical consequence is architectural. Where the database sits, who holds the key to re-identification, and which parties can access identifiable data are decisions that should be made at system design rather than negotiated after a country has been added. We map the data flow against each country's requirements at start-up and document it, because that document is what a regulator or ethics committee will ask to see.
How an engagement runs
Protocol review, endpoint and estimand definition, sample size, CRF and edit check specification, and a documented data flow mapped against country requirements.
EDC configuration, user acceptance testing, integration of external data sources, and system validation documentation.
Ongoing data review and cleaning, medical coding, reconciliation of laboratory and safety data, and centralized monitoring outputs.
Database lock, analysis per the statistical analysis plan, tables and figures, and the datasets and documentation a submission requires.
What you receive
A validated EDC with documented user acceptance testing. A data flow map assessed against each country’s requirements. A statistical analysis plan agreed before lock. Analysis datasets, tables, listings and figures ready for submission.
Evidence and context
Our operating assumptions are published rather than asserted. The Future of Clinical Trials in Africa sets out why study performance is increasingly determined by ecosystem maturity rather than site selection, and The Untapped Advantage makes the case that institutions, not regions, are the right unit of qualification. Both are available in full, with executive briefs for readers who want the argument in a shorter form.
FAQ
We design and manage studies across leading EDC platforms, selecting the right system for each study's design and data sources.
Yes, statistical analysis planning, analysis and clinical study report support are core biostatistics capabilities.
Tell us about your objectives and our multidisciplinary team will scope an integrated, flexible solution.